With a rise in respiratory illnesses like the common cold, allergies, sinusitis, and influenza, there's a corresponding increase in symptoms such as nasal congestion, sinus pressure, and runny nose. These discomforts drive individuals to seek relief, often turning to medications for symptomatic management that propels the growth of the market. For instance, as per the report published by Asthma and Allergy Foundation of America, in March 2023, more than 100 million people in the U.S. experience various types of allergies each year. Allergies are the sixth leading cause of chronic illness in the U.S. Each year in the U.S., it is estimated that anaphylaxis (a severe allergic reaction) to food results in 90,000 emergency room visits.
Furthermore, the prevalence of these respiratory ailments leads to a greater preference for over the counter (OTC) drugs. Phenylephrine-based products, readily available without a prescription, capitalize on this trend, offering consumers quick access to relief.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
The global phenylephrine drugs market was valued at USD 21.7 billion in 2023 and will grow at 6.6% CAGR during 2024-2032, driven by increase in prevalence of respiratory disease, such as common cold, allergies, and sinusitis.
The tablets segment in the phenylephrine drugs industry generated USD 8.1 billion in 2023, favored by regulatory approvals and guidelines for supporting the safety and efficacy of phenylephrine tablets.
North America phenylephrine drugs market secured 39.7% share in 2023 and is expected to grow throughout 2032, backed by respiratory conditions like common cold, allergies, sinusitis, and influenza.
Novartis AG, Perrigo Company PLC, Johnson & Johnson Consumer Inc. (Kenvue Inc.), Proctor & Gamble Co., Pfizer, Inc., Foundation Consumer Brands LLC, Mylan N.V., Torrent Pharmaceuticals, Inc., GlaxoSmithKline PLC and Bayer AG.